Monopar Therapeutics’ (MNPR) “Buy” Rating Reiterated at BTIG Research

Monopar Therapeutics (NASDAQ:MNPR)‘s stock had its “buy” rating restated by equities researchers at BTIG Research in a research report issued on Wednesday,Benzinga reports. They currently have a $104.00 price objective on the stock. BTIG Research’s target price would indicate a potential upside of 55.13% from the stock’s previous close.

Several other analysts have also issued reports on the stock. Barclays set a $125.00 price target on shares of Monopar Therapeutics and gave the stock an “overweight” rating in a research report on Monday, October 13th. Leerink Partners initiated coverage on Monopar Therapeutics in a research report on Monday, November 10th. They set an “outperform” rating and a $115.00 target price on the stock. Jones Trading upgraded Monopar Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 10th. Lake Street Capital initiated coverage on Monopar Therapeutics in a research report on Tuesday, September 23rd. They issued a “buy” rating and a $106.00 price objective for the company. Finally, Chardan Capital lifted their price objective on Monopar Therapeutics from $85.00 to $100.00 and gave the stock a “buy” rating in a report on Sunday, November 9th. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $107.00.

Monopar Therapeutics Stock Up 3.1%

Shares of NASDAQ MNPR opened at $67.04 on Wednesday. Monopar Therapeutics has a 12 month low of $24.00 and a 12 month high of $105.00. The company has a market cap of $447.83 million, a P/E ratio of -19.49 and a beta of 1.46. The business’s 50 day moving average is $75.33 and its two-hundred day moving average is $62.89.

Monopar Therapeutics (NASDAQ:MNPR) last announced its quarterly earnings data on Thursday, November 13th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.46) by ($0.02). Sell-side analysts expect that Monopar Therapeutics will post -1.65 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, CFO Quan Anh Vu purchased 1,500 shares of the firm’s stock in a transaction that occurred on Friday, December 26th. The shares were acquired at an average price of $69.95 per share, with a total value of $104,925.00. Following the purchase, the chief financial officer directly owned 1,500 shares in the company, valued at $104,925. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website. 20.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Wellington Management Group LLP acquired a new stake in shares of Monopar Therapeutics in the 3rd quarter valued at $18,904,000. Deerfield Management Company L.P. bought a new position in Monopar Therapeutics during the 3rd quarter valued at about $13,048,000. TCG Crossover Management LLC acquired a new position in Monopar Therapeutics in the third quarter valued at about $12,496,000. Vanguard Group Inc. grew its stake in Monopar Therapeutics by 140.7% during the third quarter. Vanguard Group Inc. now owns 208,218 shares of the company’s stock worth $17,005,000 after buying an additional 121,729 shares during the last quarter. Finally, Vivo Capital LLC acquired a new stake in shares of Monopar Therapeutics during the third quarter worth approximately $7,391,000. 1.83% of the stock is owned by institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel targeted radiotherapeutics and next-generation antibody-drug conjugates for the treatment of cancer. The company’s core technology leverages a pretargeted radioimmunotherapy (PRIT) platform designed to deliver potent radioisotopes to tumor cells while minimizing exposure to healthy tissues. By combining small-molecule binding agents with specialized radioisotopes, Monopar aims to improve the therapeutic index of radiation-based cancer therapies.

The company’s pipeline includes multiple oncology candidates in various stages of preclinical and early clinical development.